Romosozumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Romosozumab |
| DrugBank ID | DB11866 |
| Brand Names (EU) | Evenity |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.46% |
Approved Indication (EMA)
Evenity is indicated in treatment of severe osteoporosis in postmenopausal women at high risk of fracture.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | phosphorus metabolism disease | 99.46% | DL |
| 2 | hypercalcemia disease | 98.33% | DL |
| 3 | obsolete vitamin D deficiency | 97.83% | DL |
| 4 | nephrocalcinosis | 97.50% | DL |
| 5 | calcium-alkali syndrome | 97.44% | DL |
| 6 | primary bone dysplasia with defective bone mineralization | 97.27% | DL |
| 7 | postmenopausal osteoporosis | 95.92% | DL |
| 8 | severe nonproliferative diabetic retinopathy | 95.01% | DL |
| 9 | osteoporosis | 94.90% | DL |
| 10 | renal osteodystrophy | 94.28% | DL |
| 11 | osteomalacia (disease) | 93.47% | DL |
| 12 | pregnancy associated osteoporosis | 92.86% | DL |
| 13 | autosomal dominant neovascular inflammatory vitreoretinopathy | 92.43% | DL |
| 14 | Worth syndrome | 92.37% | DL |
| 15 | impaired renal function disease | 91.50% | DL |
| 16 | succinyl-CoA:3-ketoacid CoA transferase deficiency | 91.11% | DL |
| 17 | hypophosphatemic rickets | 89.63% | DL |
| 18 | non-renal secondary hyperparathyroidism | 89.54% | DL |
| 19 | bone remodeling disease | 88.92% | DL |
| 20 | hereditary hypophosphatemic rickets | 88.54% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.